Treatment Overview

Living with cystic fibrosis (CF) requires resilience and dedication to a daily routine that can often feel like a full-time job. For individuals with this condition, the body produces thick, sticky mucus that clogs the lungs and obstructs the digestive system. This can lead to persistent coughing, frequent lung infections, and difficulty maintaining a healthy weight. While the diagnosis is life-changing, the landscape of care has evolved dramatically in recent years.

Treatment is essential to prevent permanent lung damage, ensure proper nutrition, and extend life expectancy. The primary goals are to keep the airways clear, control infections, and assist with digestion. Because CF is a genetic condition caused by various mutations, treatment plans are highly personalized. Therapies that work for one person may not be effective for another, depending on their specific genetic profile and the severity of organ involvement (Cystic Fibrosis Foundation, 2024).

Overview of treatment options for Cystic Fibrosis

The management of cystic fibrosis is a multi-pronged approach that targets both the symptoms and the underlying genetic defect. Historically, treatment focused solely on managing the consequences of the disease: clearing mucus from the lungs and treating infections as they arose.

Today, the standard of care often involves a combination of therapies that correct the malfunctioning protein causing the disease and supportive treatments that manage daily symptoms. While chest physical therapy (such as using an inflatable vest) is a non-negotiable daily practice for airway clearance, pharmacological treatments are the engine that keeps the body functioning. Treatment typically involves a regimen of inhaled medications, oral pills, and nutritional support.

Medications used for Cystic Fibrosis

The most significant advancement in CF care is the development of CFTR modulators. This class of drugs targets the root cause of the disease. Depending on the patient’s specific genetic mutations, doctors may prescribe a combination of modulators such as elexacaftor, tezacaftor, and ivacaftor. Clinical experience suggests that for eligible patients, these drugs can dramatically improve lung function and reduce the frequency of pulmonary flare-ups.

To manage lung health, mucus thinners (mucolytics) are standard. Inhaled dornase alfa and hypertonic saline are widely used to break down the thick secretions in the airways, making them easier to cough up.

Antibiotics are crucial for preventing and treating lung infections. Patients often take inhaled antibiotics, such as tobramycin or aztreonam, on a cycling schedule (e.g., one month on, one month off) to suppress bacterial growth. Oral or intravenous antibiotics are added if an infection worsens.

For digestive health, pancreatic enzyme replacement therapy (PERT) is essential for the majority of patients. These capsules are taken with every meal and snack to help the body absorb nutrients. Multivitamins rich in fat-soluble vitamins (A, D, E, and K) are also standard (National Heart, Lung, and Blood Institute, 2023).

How these medications work

CFTR modulators work by fixing the defective protein responsible for cystic fibrosis. In people with CF, a protein “gate” on the cell surface is either missing or stuck closed, preventing the flow of salt and water. Modulators act as “correctors” to help the protein fold the right way and “potentiators” to hold the gate open. This allows salt and fluids to move continuously, thinning the mucus at the source.

Mucolytics work physically and chemically. Dornase alfa acts like microscopic scissors, cutting up the DNA strands in the mucus that make it sticky. Hypertonic saline draws water into the airways to rehydrate the mucus. Pancreatic enzymes simply replace the natural enzymes that are blocked from reaching the intestines, allowing food to be broken down and absorbed (Mayo Clinic, 2021).

Side effects and safety considerations

CFTR modulators require monitoring due to risks like elevated liver enzymes (necessitating regular blood tests) and cataracts in younger patients (requiring periodic eye exams). Common side effects include headache, stomach pain, or rash.

Antibiotic side effects range from voice changes with inhaled forms to potential kidney or hearing issues with aggressive IV use. Pancreatic enzymes are generally safe but require correct dosing to prevent constipation or intestinal irritation. Patients must seek immediate care for hemoptysis or a sudden, severe drop in breathing ability.

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. Cystic Fibrosis Foundation. https://www.cff.org
  2. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov
  3. Mayo Clinic. https://www.mayoclinic.org
  4. Centers for Disease Control and Prevention. https://www.cdc.gov

Medications for Cystic Fibrosis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Cystic Fibrosis.

Found 6 Approved Drugs for Cystic Fibrosis

Tobramycin

Brand Names
TOBI Podhaler, TOBI, Bethkis, TobraDex, Tobrex

Tobramycin

Brand Names
TOBI Podhaler, TOBI, Bethkis, TobraDex, Tobrex
Form: Injection, Ointment, Inhalant, Suspension, Capsule, Solution
Method of administration: Respiratory (inhalation), Oral, Intravenous, Intramuscular, Ophthalmic
FDA approval date: June 28, 1981
Classification: Corticosteroid
Tobramycin injection is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa, E. coli, and Klebsiella sp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella sp, Enterobacter sp, Serratia sp, E. coli, and S. aureus (penicillinase- and non-penicillinase-producing strains) Serious central-nervous-system infections (meningitis) caused by susceptible organisms Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella sp, and Enterobacter sp Skin, bone, and skin structure infections caused by P. aeruginosa, Proteus sp, E. coli, Klebsiella sp, Enterobacter sp and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus sp, (indole-positive and indole- negative), E. coli, Klebsiella sp, Enterobacter sp, Serratia sp, S. aureus, Providencia sp, and Citrobacte r sp. Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram- negative infection is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection and other antimicrobial drugs, Tobramycin Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Ivacaftor

Brand Names
Trikafta, Kalydeco, Symdeko, Orkambi

Ivacaftor

Brand Names
Trikafta, Kalydeco, Symdeko, Orkambi
Form: Tablet, Kit, Granule
Method of administration: Oral
FDA approval date: January 31, 2012
Classification: Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data [see Clinical Pharmacology (1.

Azithromycin

Brand Names
Azasite, Zithromax

Azithromycin

Brand Names
Azasite, Zithromax
Form: Injection, Tablet, Powder, Suspension, Solution
Method of administration: Oral, Intravenous, Parenteral, Ophthalmic
FDA approval date: September 28, 1994
Classification: Macrolide Antimicrobial
Azithromycin for oral suspension USP is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications.

Pulmozyme

Generic Name
Dornase

Pulmozyme

Generic Name
Dornase
Form: Solution
Method of administration: Respiratory (inhalation)
FDA approval date: December 30, 1993
Classification: Recombinant Human Deoxyribonuclease 1
PULMOZYME ® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. PULMOZYME is a recombinant DNase enzyme indicated in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function. ( 1 )

Aztreonam

Brand Names
Cayston, Azactam, Emblaveo

Aztreonam

Brand Names
Cayston, Azactam, Emblaveo
Form: Injection, Kit, Powder
Method of administration: Intravenous, Intramuscular
FDA approval date: November 05, 2009
Classification: Monobactam Antibacterial
To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections, including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections, including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. *Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections, including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. Concurrent Therapy Concurrent initial therapy with other antimicrobial agents and aztreonam for injection is recommended before the causative organism(s) is known in seriously ill patients who are also at risk of having an infection due to Gram-positive aerobic pathogens. If anaerobic organisms are also suspected as etiologic agents, therapy should be initiated using an anti-anaerobic agent concurrently with aztreonam for injection. Certain antibiotics (e.g., cefoxitin, imipenem) may induce high levels of beta-lactamase in vitro in some Gram-negative aerobes such as Enterobacter and Pseudomonas species, resulting in antagonism to many beta-lactam antibiotics including aztreonam. These in vitro findings suggest that such beta-lactamase-inducing antibiotics not be used concurrently with aztreonam. Following identification and susceptibility testing of the causative organism(s), appropriate antibiotic therapy should be continued.
Showing 1-5 of 6
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances